Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

The Strategy trailed its core benchmark but bested its growth index, supported by strength among communication services and ...

The new hospital, officially named the Novo CHUAC (New University Hospital of A Coruña), is one of the most ambitious public ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic ...

Meghan Trainor and husband Daryl Sabara opened up about their health journeys, which has included them both opting to take ...

The Harbor International Compounders ETF returned -9.22% compared to the MSCI All Country World ex-US Index, which returned ...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.